Enacting laws at the state level that would restrict the substitution of biosimilar drugs would raise costs for patients and employers and compete with forthcoming federal laws, the Pharmaceutical Care Management Association says. "Creating a patchwork of dueling state and federal rules would make it harder for pharmacists to know when they can dispense a biosimilar," according to PCMA. "That would raise costs for patients and their employers, who typically cover two-thirds of prescription drug benefit costs."

Full Story:
AIS Health

Related Summaries